Filing Flows › Comparisons › MREO vs MNOV
Mereo BioPharma Group vs Medicinova: MREO and MNOV compared
Mereo BioPharma Group is the larger company: $500K of revenue in its latest quarter (Q2 2025) against $458K for Medicinova (Q2 2026).
Where the money goes: MREO and MNOV
Mereo BioPharma Group (MREO) · Q2 2025
Mereo BioPharma Group, Q2 2025: revenue $500K, net loss $14.6M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
Medicinova (MNOV) · Q2 2026
Medicinova, Q2 2026: revenue $458K (+241% year over year), operating margin -554.3%, net loss $2.3M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Mereo BioPharma Group (MREO) | Medicinova (MNOV) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q2 2026 |
| Revenue | $500K | $458K |
| Revenue growth, Y/Y | — | +241% |
| Operating margin | n/m | -554.3% |
| Net earnings | −$14.6M | −$2.3M |
| Net margin | — | -504.8% |
| Operating cash flow | −$7.7M | −$1.9M |
Questions
Which is bigger, Mereo BioPharma Group or Medicinova?
Mereo BioPharma Group is the larger company: $500K of revenue in its latest quarter (Q2 2025) against $458K for Medicinova (Q2 2026).
More: Mereo BioPharma Group earnings · how Mereo BioPharma Group makes money · Medicinova earnings · how Medicinova makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2025; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.